News Search Results
Nov 07, 2025, 09:00 ET CREATE Medicines Announces Positive First-in-Human Results for MT-302
CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- CREATE Medicines Inc. (formerly Myeloid Therapeutics), a biotechnology company advancing in vivo immune-cell programming with mRNA-LNP therapeutics, today announced first-in-human results from its Phase 1 MYE Symphony
More news about: CREATE Medicines, Inc.
Nov 07, 2025, 09:00 ET Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation & immunology (I&I), today announced updated interim results from
More news about: Marengo Therapeutics
Nov 07, 2025, 08:58 ET Resonant Wins BioTech Breakthrough Awards' "DNA Sequencing Innovation Of The Year"
Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics,
More news about: Resonant
Nov 07, 2025, 08:31 ET MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of positive new data from its Phase 2a clinical trial
More news about: MetaVia Inc.
Nov 07, 2025, 08:30 ET Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today announced the publication of results
More news about: Brii Biosciences Limited
Nov 07, 2025, 08:30 ET 騰盛博藥宣佈在《自然-醫學》發表ENSURE II期研究結果
Elebsiran是一種經皮下注射給藥的靶向乙型肝炎病毒（HBV）的小干擾核糖核酸（siRNA）研究性藥物，旨在降解HBV RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及丁型肝炎病毒（HDV）的直接抗病毒活性。其是首個進入臨床的採用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc. 獲得了在大中華地區開發和商業化elebsiran的獨家權益。2024年5月，中國國家藥品監督管理局（NMPA）藥品審評中心（CDE）授予elebsiran突破性治療品種認定。 關於騰盛博藥
More news about: 騰盛博藥生物科技有限公司
Nov 07, 2025, 08:30 ET IRB & ICF Approval Simplified: 5 Key Considerations and Mistakes, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 07, 2025, 08:30 ET FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Nov 07, 2025, 08:00 ET Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors
SAN FRANCISCO and KYOTO, Japan, Nov. 7, 2025 /PRNewswire/ -- Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS therapies, today announced the appointment of Laurent Fischer, MD, as its first independent
More news about: Shinobi Therapeutics
Nov 07, 2025, 07:30 ET Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Nov 06, 2025, 23:37 ET Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Nov 06, 2025, 21:00 ET Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
effect. About Argo Biopharma Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd
Nov 06, 2025, 16:28 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial
More news about: Hagens Berman Sobol Shapiro LLP
Nov 06, 2025, 16:16 ET Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
Development at Liberty City Ventures, appointed as President of the Company. The existing management team will continue to oversee its clinical-stage biotechnology operations. Mark Wendland will also join the Board of Directors of the Company. "Closing this financing represents an important
More news about: Tharimmune, Inc.
Nov 06, 2025, 16:15 ET Nektar Therapeutics Reports Third Quarter 2025 Financial Results
About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Nov 06, 2025, 16:05 ET Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 06, 2025, 16:05 ET Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
Highlights & Strategic Positioning We believe AI models will impact biotechnology in two ways and Ginkgo is well-positioned to provide tools in bothFirst, we see reasoning models controlling lab automation.
More news about: Ginkgo Bioworks
Nov 06, 2025, 16:02 ET Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov. 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Nov 06, 2025, 16:00 ET Curis Provides Third Quarter 2025 Business Update
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial
More news about: Curis, Inc.
Nov 06, 2025, 14:53 ET Angel Yeast nimmt neue Produktionslinie für Hefeproteine mit einer Kapazität von 11.000 Tonnen in Betrieb, um die weltweite Nachfrage nach nachhaltiger Ernährung zu decken
Angel Yeast Co., Ltd. (SH600298) hat den Betrieb seiner Produktionslinie für Hefeproteine der nächsten Generation im Baiyang Biotechnology Park in Yichang, Hubei, offiziell aufgenommen. Die Anlage verfügt über eine jährliche Produktionskapazität von 11.000 Tonnen hochreinem Hefeprotein
More news about: Angel Yeast
Nov 06, 2025, 13:54 ET Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 06, 2025, 12:12 ET TEDCO Announces Signing of an Agreement Enabling up to $50 Million Investment Capital from Taiwanese APAC Investment and Innovation Development Association TAIWAN (TAIIDA) and SFIC Group
AI, deep tech, robotics, semiconductor-related industries, agricultural technology and biotechnology. Several of these identified industries intersect with Maryland's lighthouse sectors of life sciences (biotechnology and agricultural technology), I.T. (AI and deep tech), and aerospace and defense.
More news about: TEDCO
Nov 06, 2025, 10:45 ET Pharmacovigilance Market to Reach $26.2 billion, Globally, by 2034 at 12.3% CAGR: Allied Market Research
incidences of adverse drug reactions (ADRs), and the growing emphasis on patient safety by global regulatory authorities. As pharmaceutical and biotechnology companies expand their pipelines to include biologics, biosimilars, gene therapies, and personalized medicines, the need for continuous safety surveillance
More news about: Allied Market Research
Nov 06, 2025, 10:10 ET Global Telehealth Market Size to Exceed USD 156.3 Billion by 2035, Rising at 19.15% CAGR | Report by Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Nov 06, 2025, 10:00 ET Congruence Therapeutics to Present Preclinical Characterization of its MC4R Corrector Development Candidate CGX-926 for Genetic Obesity at ObesityWeek 2025
MONTREAL, Nov. 6, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, today announced that it will present a poster
More news about: Congruence Therapeutics